7210 Wareham Drive, Tampa, FL 33647
Dec. 4, 2024 StatNews.com today reported that…. Eli Lilly’s drug Zepbound resulted in weight loss that was 47% greater than the weight loss achieved with Wegovy, the rival medicine made by Novo Nordisk, according to a new head-to-head study out this morning. The news likely will not be entirely surprising to the physicians and scientists […]
Zepbound Beats Wegovy for Weight Loss Read More »
Nov. 6, 2024 WW (Weight Watchers) reported results for the 3rd quarter 2024 today. “For over six decades, Weight Watchers has been the trusted leader in weight management, offering a full spectrum of science-backed, proven weight management solutions. With our expanded clinical offering, iconic trusted brand, and global community of members, we are well-equipped to
Weight Watchers Reports 3rd Quarter Results Read More »
Nov. 4, 2024 Medifast reported Q3 results today. CEO Dan Chard said: “With tailored plans, personal solutions and a focused approach to driving customer acquisition, we believe that our strategy can drive sustainable growth in the quarters and years ahead.” Third Quarter 2024 Revenue of $140.2 million, with revenue per active earning coach of $4,672
Medifast Reports 3rd Quarter Results Read More »
Oct. 8, 2024 WW announced the addition of compounded semaglutide into its offering, broadening eligible members’ access to clinical weight management interventions. The new offering, starting at $129, enhances the Company’s holistic weight management program, which includes behavioral and clinical solutions with support from board-certified clinicians, registered dietitians, and the global Weight Watchers community. This
Weight Watchers Adds Compounded Meds Read More »
Sept. 25, 2024 Lindora Clinics, a regional medical weight loss chain based in California, has recently begun franchising. As such, it has filed a 2024 FDD (Franchise Disclosure Document) that describes the franchise, its investment costs, etc. Lindora is a long-established company in the weight loss market, with a variety of weight loss programs, both
Lindora Clinics Franchise Is Well Diversified Read More »
Sept. 24, 2024 Marketdata LLC, DietBusinessWatch.com’s parent), estimates that the top competitors in the U.S. weight loss market lost at least $971 million in revenues last year, due to the juggernaut of GLP-1 medications. This is a huge transfer of sales from commercial and retail weight loss programs and product segments to medical programs. Here’s
Weight Loss Market’s Leaders Lost At Least $971 Million in 2023 Read More »
Sept. 23, 2024 According to Becker’s Hospital Review… On Sept. 24, Novo Nordisk CEO Lars Fruergaard Jørgensen is slated to testify at a Senate committee hearing about the costs for Wegovy and Ozempic. The hearing comes after months of disagreements between Denmark-based Novo Nordisk and the Senate Committee on Health, Education, Labor and Pensions. The
GLP-1 Drugs Market Update Read More »
Sept. 12, 2024 Noom is the latest weight loss company to start prescribing compounded versions of the obesity medication semaglutide. This follows similar moves by Hims, Ro, and other telehealth companies capitalizing on shortages of brand-name obesity drugs. Noom will sell the compounded GLP-1 drug starting at $149 a month, it says. The company, which
Noom Offers Compounded Weight Loss Drugs Read More »
August 14, 2024 Nearly half of online pharmacies that sell semaglutide — the active ingredient in Ozempic and Wegovy — are doing so illegally, posing safety risks for consumers, according to a study published Aug. 2 in JAMA Network Open. Of the 317 online pharmacies included in the study, researchers found 42.27% were operating illegally, meaning
Study finds that 42% of online pharmacies selling semaglutide are illegal Read More »
August 5, 2024 Wellness company Medifast (NYSE:MED) fell short of analysts’ expectations. Management said that: “We are acting decisively to transform our business to position us for long-term growth, with a strong balance sheet free of debt, a clear focus on new customer acquisition, and a broader health and wellness offer to a significantly expanded
Medifast Reports Q2 Results Read More »